secwatch.observer — SEC 8-K summary
======================================

Issuer:     Sarepta Therapeutics, Inc. (SRPT)
CIK:        0000873303
Form:       8-K
Filed at:   2023-06-09T23:59:59+00:00
Accession:  0000950170-23-027276
Event type: other_material
Sentiment:  negative
Materiality: 0.60
Item codes: 5.02, 5.07, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Sarepta shareholders reject executive compensation in advisory vote; approve equity plan amendments
--------------------------------------------------------------------------------

- Advisory vote on 2022 named executive officer compensation failed: 52.8M against vs 20.4M for.
- Approved Amendment No. 3 to 2018 Equity Incentive Plan, increasing authorized shares by 2.5M to 13.2M.
- Approved Amendment No. 2 to ESPP, increasing authorized shares by 300K to 1.4M.
- Re-elected directors Barry, Behrens, Mayo, Nicaise as Class II members for two-year terms.
- Advisory vote on frequency of future executive compensation votes: one year approved with 73M votes.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/873303/000095017023027276/0000950170-23-027276-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/873303/000095017023027276/srpt-20230608.htm
  HTML page:      https://secwatch.observer/filing/0000950170-23-027276

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer